- Home
- ROIV vs ALV Comparison
ROIV vs ALV Comparison
Compare ROIV & ALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | ALV |
|---|---|---|
| Founded | 2014 | 1953 |
| Country | United Kingdom | Sweden |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 9.7B |
| IPO Year | N/A | 1997 |
Fundamental Metrics
Financial Performance| Metric | ROIV | ALV |
|---|---|---|
| Price | $22.48 | $119.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 11 |
| Target Price | $24.31 | ★ $133.45 |
| AVG Volume (30 Days) | ★ 8.3M | 516.9K |
| Earning Date | 02-09-2026 | 01-30-2026 |
| Dividend Yield | N/A | ★ 2.84% |
| EPS Growth | N/A | ★ 25.57 |
| EPS | N/A | ★ 9.69 |
| Revenue | $20,329,000.00 | ★ $10,614,000,000.00 |
| Revenue This Year | N/A | $4.73 |
| Revenue Next Year | $741.42 | $4.40 |
| P/E Ratio | ★ N/A | $12.37 |
| Revenue Growth | N/A | ★ 0.85 |
| 52 Week Low | $8.73 | $75.49 |
| 52 Week High | $23.47 | $129.54 |
Technical Indicators
Market Signals| Indicator | ROIV | ALV |
|---|---|---|
| Relative Strength Index (RSI) | 61.36 | 51.46 |
| Support Level | $21.60 | $118.76 |
| Resistance Level | $22.76 | $121.80 |
| Average True Range (ATR) | 0.84 | 2.01 |
| MACD | 0.04 | 0.12 |
| Stochastic Oscillator | 70.91 | 56.18 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About ALV Autoliv Inc.
Autoliv Inc is the world-wide leader in passive safety components and systems for the auto industry. Products include seat belts, frontal air bags, side-impact air bags, air bag inflators, and steering wheels. The Renault-Nissan-Mitsubishi alliance is the company's largest customer at 10% of 2023 revenue, with Stellantis accounting for 10% and Volkswagen 9%. At 34% of 2023 revenue, the Americas was Autoliv's largest geographic region, followed by Europe at 27%, China at 20%, and rest of world at 19%.